Analysts Set Elanco Animal Health Incorporated (NYSE:ELAN) Target Price at $29.09

Elanco Animal Health Incorporated (NYSE:ELAN) has been given an average rating of “Moderate Buy” by the thirteen brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, nine have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $29.0909.

A number of equities research analysts recently commented on ELAN shares. Morgan Stanley increased their price target on Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 22nd. Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. KeyCorp raised their price target on shares of Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. TD Cowen boosted their price target on shares of Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, June 18th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Kurzius bought 40,000 shares of Elanco Animal Health stock in a transaction dated Thursday, August 20th. The stock was bought at an average cost of $23.40 per share, with a total value of $936,000.00. Following the completion of the acquisition, the director directly owned 188,647 shares in the company, valued at approximately $4,414,339.80. The trade was a 26.91% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Michael Harrington purchased 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were acquired at an average cost of $21.82 per share, with a total value of $109,100.00. Following the completion of the transaction, the director directly owned 131,451 shares of the company’s stock, valued at $2,868,260.82. The trade was a 3.95% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have bought 63,198 shares of company stock worth $1,473,109. 1.14% of the stock is owned by insiders.

Institutional Investors Weigh In On Elanco Animal Health

A number of hedge funds have recently made changes to their positions in the business. BlackRock Inc. bought a new position in Elanco Animal Health during the second quarter valued at about $1,202,198,000. Primecap Management Co. CA purchased a new position in Elanco Animal Health in the second quarter valued at about $1,118,402,000. California State Teachers Retirement System boosted its stake in Elanco Animal Health by 2,358.9% in the second quarter. California State Teachers Retirement System now owns 14,186,139 shares of the company’s stock valued at $349,121,000 after acquiring an additional 13,609,203 shares during the last quarter. The Manufacturers Life Insurance Company bought a new position in shares of Elanco Animal Health during the 2nd quarter valued at approximately $205,636,000. Finally, UBS Group AG increased its stake in shares of Elanco Animal Health by 56.7% during the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock worth $331,669,000 after purchasing an additional 5,961,457 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors.

Elanco Animal Health Trading Down 2.3%

ELAN opened at $23.95 on Wednesday. Elanco Animal Health has a fifty-two week low of $18.22 and a fifty-two week high of $27.98. The firm has a market capitalization of $11.96 billion, a PE ratio of -58.41, a P/E/G ratio of 1.83 and a beta of 1.68. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. The company’s 50-day moving average is $24.63 and its 200 day moving average is $23.96.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The business had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. During the same quarter in the previous year, the business earned $0.26 EPS. The company’s quarterly revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, research analysts predict that Elanco Animal Health will post 1.12 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.